Drug intelligence / Profile preview

TIDAL-02

Development stage: Preclinical
Lead developer: Turnstone Biologics
Modality: Cell Therapies

Overview

TIDAL-02 is a next-generation Selected Tumor-Infiltrating Lymphocyte (TIL) therapy that was in preclinical development by Turnstone Biologics. It was being developed as a potential treatment for solid tumors, utilizing the patient's own immune cells to target and eliminate cancer. Turnstone Biologics, the company developing TIDAL-02, was acquired by XOMA Royalty Corporation, and its operations were subsequently wound down.

Beyond the preview

Go deeper on TIDAL-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TIDAL-02.

Explore the full profile